R42 Group Company Profile
Background
Overview
Founded in 2004, R42 Group is a venture capital firm headquartered in Stanford, California. The firm specializes in inventing and financing deep science ventures, collaborating with companies from the pre-seed stage through to growth. R42 Group focuses on sectors such as information technology, healthcare, life sciences, big data, the Internet of Things (IoT), artificial intelligence (AI), and machine learning.
Mission and Vision
R42 Group is dedicated to supporting passionate teams developing revolutionary technologies that address pressing global needs. Leveraging expertise in science, strategic planning, financing, and a global network, the firm aims to transform innovative ideas into reality.
Key Strategic Focus
Core Objectives
R42 Group's primary objective is to invest in and nurture deep science ventures that demonstrate strong growth potential and innovative solutions. The firm provides both capital and strategic guidance to help companies scale and succeed.
Areas of Specialization
The firm specializes in sectors including:
- Information Technology
- Healthcare
- Life Sciences
- Big Data
- Internet of Things (IoT)
- Artificial Intelligence (AI)
- Machine Learning
Key Technologies Utilized
R42 Group employs advanced technologies such as AI and machine learning to identify and support ventures with high innovation potential.
Primary Markets Targeted
The firm targets markets with significant growth potential and unmet needs, particularly in the United States.
Financials and Funding
Funding History
R42 Group has made 89 investments, with 60 companies currently in its portfolio and 15 exits.
Notable Investments
- Xwatts: Invested in July 2024 during a seed round in the business/productivity software sector.
- Hayden AI: Invested in July 2024 in the business/productivity software industry.
- turn.bio: Invested in May 2024 in the drug discovery sector.
- Rubedo: Invested in April 2024 in the drug discovery sector.
- Acrobat Genomics: Invested in April 2024 in the discovery tools (healthcare) sector.
- SENISCA: Invested in March 2024 in the drug discovery sector.
- S2 Genomics: Invested in January 2024 in the other devices and supplies sector.
- Agemica: Invested in December 2023 in the biotechnology sector.
- Reservoir Neuroscience: Invested in November 2023 during a seed round in the drug discovery sector.
- Xwatts: Invested in October 2023 during a seed round in the business/productivity software sector.
Notable Exits
- Aromyx: Exited in March 2024.
- ExpressCells: Exited in December 2023.
- Kitchology: Exited in July 2023.
- Tertill: Exited in June 2023.
- Riven: Exited in October 2022.
- Civil Maps: Exited in June 2022.
- Embee Mobile: Exited in November 2021.
- Cradlepoint: Exited in November 2020.
- SQZ Biotech: Exited in October 2020.
- Kaptivo: Exited in August 2020.
Intended Utilization of Capital
The firm utilizes its capital to support the development and growth of its portfolio companies, providing both financial resources and strategic guidance.
Pipeline Development
Key Pipeline Candidates
R42 Group's portfolio includes companies at various stages of development, particularly in the healthcare and life sciences sectors. Notable investments include:
- turn.bio: Engaged in drug discovery, currently in clinical trials.
- Rubedo: Focused on drug discovery, in pre-clinical trials.
- SENISCA: Specializing in drug discovery, in pre-clinical trials.
- Reservoir Neuroscience: Involved in drug discovery, in product development.
Target Conditions
These companies target a range of conditions, including various cancers and age-related diseases.
Timelines for Anticipated Milestones
Specific timelines for milestones vary by company and are subject to change based on development progress and regulatory approvals.
Technological Platform and Innovation
Proprietary Technologies
R42 Group leverages advanced technologies such as AI and machine learning to identify and support ventures with high innovation potential.
Significant Scientific Methods
The firm employs scientific methodologies, including machine learning algorithms, to assess and invest in companies with groundbreaking technologies.
Leadership Team
Key Executive Profiles
